Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT05673083
Active, not recruiting Observational

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

NCT05673083 · tracked via the Priya Life Science USA tracker
Sponsor
All4Cure
Phase
Observational
Started
2023-03-01
Last updated
2025-09-04

Condition(s) studied

Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma, RefractoryMultiple Myeloma With Failed Remission

Study summary

The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are:

• Does All4Cure effect patient activation as assessed by the PAM-13 survey?

Participants will be asked to:

* fill out quarterly PAM-13 surveys through the All4Cure website to assess patient activation.
* fill out monthly Patient Reported Outcome (PRO) surveys through the All4Cure website.
* fill out a baseline and exit All4Cure surveys through the All4Cure website to assess patient perceptions of All4Cure at the beginning and the end of the study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. have a diagnosis of multiple myeloma. 2. are aged 18 years and older. 3. can read and e-consent to participate in the study. 4. can speak English. 5. can complete surveys at pre-specified intervals. 6. have access to a device that would allow for the completion of surveys (including at home, at work, at the oncologist's office or elsewhere). 7. are cared for by a physician who is enrolled in All4Cure. Exclusion Criteria: 1\. Patients will be excluded who are unable to engage with All4Cure or are already participants in All4Cure.

Primary outcome measure(s)

  • Patient Activation — 24 months
    Patient activation emphasizes patients' willingness and ability to take independent actions to manage their health and care. A widely used definition equates patient activation with understanding one's role in the care process and having the knowledge, skill, and confidence to manage one's health and health care. A growing body of evidence shows that patients who are more activated have better health outcomes and care experiences. This will be assessed through the PAM-13 survey which has a scale of 1-4, with 4 being the highest level of patient activation and associated with the best patient outcomes and 1 being the lowest level of patient activation.

Trial sites (7)

FacilityCityRegionStatus
Highlands Oncology Group Fayetteville Arkansas
Cancer Specialists of North Florida Jacksonville Florida
Misson Cancer + Blood Des Moines Iowa
Hematology-Oncology Associates of Central New York East Syracuse New York
Oklahoma Cancer Specialists and Research Institute Tulsa Oklahoma
Oncology Consultants Houston Texas
Northwest Medical Specialties PLLC Tacoma Washington

More All4Cure trials in the USA

A Crowd Sourcing Platform for Patients With Cancer Recruiting
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma Recruiting

Other trials for the same condition

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) Active, not recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments Recruiting
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05673083 on ClinicalTrials.gov ↗ ← All trials in the USA